Logo image of CLS

CELESTICA INC (CLS) Stock Fundamental Analysis

USA - NYSE:CLS - CA15101Q2071 - Common Stock

331.86 USD
-12.75 (-3.7%)
Last: 11/11/2025, 8:04:00 PM
335.06 USD
+3.2 (+0.96%)
Pre-Market: 11/12/2025, 5:05:50 AM
Fundamental Rating

7

Taking everything into account, CLS scores 7 out of 10 in our fundamental rating. CLS was compared to 123 industry peers in the Electronic Equipment, Instruments & Components industry. CLS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CLS is not overvalued while it is showing excellent growth. This is an interesting combination. This makes CLS very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

CLS had positive earnings in the past year.
In the past year CLS had a positive cash flow from operations.
In the past 5 years CLS has always been profitable.
CLS had a positive operating cash flow in each of the past 5 years.
CLS Yearly Net Income VS EBIT VS OCF VS FCFCLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

CLS's Return On Assets of 10.85% is amongst the best of the industry. CLS outperforms 90.24% of its industry peers.
The Return On Equity of CLS (35.33%) is better than 93.50% of its industry peers.
CLS has a better Return On Invested Capital (21.33%) than 94.31% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CLS is in line with the industry average of 9.58%.
The last Return On Invested Capital (21.33%) for CLS is above the 3 year average (11.43%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 10.85%
ROE 35.33%
ROIC 21.33%
ROA(3y)4.63%
ROA(5y)3.55%
ROE(3y)15.02%
ROE(5y)11.3%
ROIC(3y)11.43%
ROIC(5y)8.93%
CLS Yearly ROA, ROE, ROICCLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

CLS has a better Profit Margin (6.35%) than 71.54% of its industry peers.
CLS's Profit Margin has improved in the last couple of years.
CLS's Operating Margin of 7.33% is fine compared to the rest of the industry. CLS outperforms 69.92% of its industry peers.
CLS's Operating Margin has improved in the last couple of years.
The Gross Margin of CLS (12.04%) is worse than 75.61% of its industry peers.
In the last couple of years the Gross Margin of CLS has grown nicely.
Industry RankSector Rank
OM 7.33%
PM (TTM) 6.35%
GM 12.04%
OM growth 3Y24.27%
OM growth 5Y29.03%
PM growth 3Y34%
PM growth 5Y30.13%
GM growth 3Y8.03%
GM growth 5Y10.39%
CLS Yearly Profit, Operating, Gross MarginsCLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CLS is creating value.
CLS has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLS has less shares outstanding
CLS has a worse debt/assets ratio than last year.
CLS Yearly Shares OutstandingCLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CLS Yearly Total Debt VS Total AssetsCLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

An Altman-Z score of 7.45 indicates that CLS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.45, CLS belongs to the best of the industry, outperforming 82.93% of the companies in the same industry.
The Debt to FCF ratio of CLS is 1.97, which is an excellent value as it means it would take CLS, only 1.97 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.97, CLS is in the better half of the industry, outperforming 76.42% of the companies in the same industry.
CLS has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
CLS's Debt to Equity ratio of 0.37 is on the low side compared to the rest of the industry. CLS is outperformed by 63.41% of its industry peers.
Although CLS does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF 1.97
Altman-Z 7.45
ROIC/WACC2.58
WACC8.28%
CLS Yearly LT Debt VS Equity VS FCFCLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.47 indicates that CLS should not have too much problems paying its short term obligations.
The Current ratio of CLS (1.47) is worse than 77.24% of its industry peers.
CLS has a Quick Ratio of 1.47. This is a bad value and indicates that CLS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CLS (0.88) is worse than 85.37% of its industry peers.
The current and quick ratio evaluation for CLS is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 0.88
CLS Yearly Current Assets VS Current LiabilitesCLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

9

3. Growth

3.1 Past

CLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.90%, which is quite impressive.
Measured over the past years, CLS shows a very strong growth in Earnings Per Share. The EPS has been growing by 48.11% on average per year.
CLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.09%.
The Revenue has been growing by 10.38% on average over the past years. This is quite good.
EPS 1Y (TTM)47.9%
EPS 3Y44.1%
EPS 5Y48.11%
EPS Q2Q%51.92%
Revenue 1Y (TTM)22.09%
Revenue growth 3Y19.63%
Revenue growth 5Y10.38%
Sales Q2Q%27.79%

3.2 Future

The Earnings Per Share is expected to grow by 38.14% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 27.74% on average over the next years. This is a very strong growth
EPS Next Y49.74%
EPS Next 2Y45.82%
EPS Next 3Y44.54%
EPS Next 5Y38.14%
Revenue Next Year24.45%
Revenue Next 2Y28.03%
Revenue Next 3Y29.6%
Revenue Next 5Y27.74%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLS Yearly Revenue VS EstimatesCLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5B 10B 15B 20B 25B
CLS Yearly EPS VS EstimatesCLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5 10

4

4. Valuation

4.1 Price/Earnings Ratio

CLS is valuated quite expensively with a Price/Earnings ratio of 62.85.
CLS's Price/Earnings is on the same level as the industry average.
CLS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.35.
Based on the Price/Forward Earnings ratio of 39.81, the valuation of CLS can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as CLS.
The average S&P500 Price/Forward Earnings ratio is at 33.72. CLS is around the same levels.
Industry RankSector Rank
PE 62.85
Fwd PE 39.81
CLS Price Earnings VS Forward Price EarningsCLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

CLS's Enterprise Value to EBITDA is on the same level as the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as CLS.
Industry RankSector Rank
P/FCF 95.87
EV/EBITDA 39.07
CLS Per share dataCLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
CLS has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CLS's earnings are expected to grow with 44.54% in the coming years.
PEG (NY)1.26
PEG (5Y)1.31
EPS Next 2Y45.82%
EPS Next 3Y44.54%

0

5. Dividend

5.1 Amount

No dividends for CLS!.
Industry RankSector Rank
Dividend Yield N/A

CELESTICA INC

NYSE:CLS (11/11/2025, 8:04:00 PM)

Premarket: 335.06 +3.2 (+0.96%)

331.86

-12.75 (-3.7%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)10-27 2025-10-27/amc
Earnings (Next)01-27 2026-01-27/amc
Inst Owners75.85%
Inst Owner Change0.34%
Ins Owners0.52%
Ins Owner Change0.42%
Market Cap38.18B
Revenue(TTM)11.28B
Net Income(TTM)716.70M
Analysts81.11
Price Target193.68 (-41.64%)
Short Float %4.39%
Short Ratio1.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.15%
Min EPS beat(2)6.6%
Max EPS beat(2)11.71%
EPS beat(4)4
Avg EPS beat(4)6.73%
Min EPS beat(4)1.95%
Max EPS beat(4)11.71%
EPS beat(8)8
Avg EPS beat(8)9.68%
EPS beat(12)12
Avg EPS beat(12)8.66%
EPS beat(16)16
Avg EPS beat(16)9.16%
Revenue beat(2)2
Avg Revenue beat(2)6.2%
Min Revenue beat(2)5%
Max Revenue beat(2)7.4%
Revenue beat(4)3
Avg Revenue beat(4)3.54%
Min Revenue beat(4)-0.75%
Max Revenue beat(4)7.4%
Revenue beat(8)7
Avg Revenue beat(8)3.49%
Revenue beat(12)11
Avg Revenue beat(12)3.14%
Revenue beat(16)14
Avg Revenue beat(16)3.37%
PT rev (1m)20.21%
PT rev (3m)15.09%
EPS NQ rev (1m)14.35%
EPS NQ rev (3m)14.35%
EPS NY rev (1m)5.77%
EPS NY rev (3m)21.03%
Revenue NQ rev (1m)9.98%
Revenue NQ rev (3m)9.98%
Revenue NY rev (1m)4.1%
Revenue NY rev (3m)9.42%
Valuation
Industry RankSector Rank
PE 62.85
Fwd PE 39.81
P/S 3.38
P/FCF 95.87
P/OCF 69.12
P/B 18.82
P/tB 27.03
EV/EBITDA 39.07
EPS(TTM)5.28
EY1.59%
EPS(NY)8.34
Fwd EY2.51%
FCF(TTM)3.46
FCFY1.04%
OCF(TTM)4.8
OCFY1.45%
SpS98.07
BVpS17.63
TBVpS12.28
PEG (NY)1.26
PEG (5Y)1.31
Graham Number45.77
Profitability
Industry RankSector Rank
ROA 10.85%
ROE 35.33%
ROCE 26.62%
ROIC 21.33%
ROICexc 23.67%
ROICexgc 30.35%
OM 7.33%
PM (TTM) 6.35%
GM 12.04%
FCFM 3.53%
ROA(3y)4.63%
ROA(5y)3.55%
ROE(3y)15.02%
ROE(5y)11.3%
ROIC(3y)11.43%
ROIC(5y)8.93%
ROICexc(3y)13.32%
ROICexc(5y)10.55%
ROICexgc(3y)18.44%
ROICexgc(5y)14.81%
ROCE(3y)14.26%
ROCE(5y)11.14%
ROICexgc growth 3Y31.4%
ROICexgc growth 5Y28.76%
ROICexc growth 3Y37.65%
ROICexc growth 5Y29.81%
OM growth 3Y24.27%
OM growth 5Y29.03%
PM growth 3Y34%
PM growth 5Y30.13%
GM growth 3Y8.03%
GM growth 5Y10.39%
F-Score7
Asset Turnover1.71
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF 1.97
Debt/EBITDA 0.76
Cap/Depr 94.54%
Cap/Sales 1.37%
Interest Coverage 15.59
Cash Conversion 55.82%
Profit Quality 55.56%
Current Ratio 1.47
Quick Ratio 0.88
Altman-Z 7.45
F-Score7
WACC8.28%
ROIC/WACC2.58
Cap/Depr(3y)94.48%
Cap/Depr(5y)73.42%
Cap/Sales(3y)1.62%
Cap/Sales(5y)1.34%
Profit Quality(3y)94.3%
Profit Quality(5y)151.44%
High Growth Momentum
Growth
EPS 1Y (TTM)47.9%
EPS 3Y44.1%
EPS 5Y48.11%
EPS Q2Q%51.92%
EPS Next Y49.74%
EPS Next 2Y45.82%
EPS Next 3Y44.54%
EPS Next 5Y38.14%
Revenue 1Y (TTM)22.09%
Revenue growth 3Y19.63%
Revenue growth 5Y10.38%
Sales Q2Q%27.79%
Revenue Next Year24.45%
Revenue Next 2Y28.03%
Revenue Next 3Y29.6%
Revenue Next 5Y27.74%
EBIT growth 1Y62.33%
EBIT growth 3Y48.65%
EBIT growth 5Y42.42%
EBIT Next Year58.36%
EBIT Next 3Y30.72%
EBIT Next 5Y38.43%
FCF growth 1Y48.75%
FCF growth 3Y20.17%
FCF growth 5Y2.76%
OCF growth 1Y40.82%
OCF growth 3Y27.84%
OCF growth 5Y6.55%

CELESTICA INC / CLS FAQ

Can you provide the ChartMill fundamental rating for CELESTICA INC?

ChartMill assigns a fundamental rating of 7 / 10 to CLS.


What is the valuation status for CLS stock?

ChartMill assigns a valuation rating of 4 / 10 to CELESTICA INC (CLS). This can be considered as Fairly Valued.


How profitable is CELESTICA INC (CLS) stock?

CELESTICA INC (CLS) has a profitability rating of 8 / 10.


How financially healthy is CELESTICA INC?

The financial health rating of CELESTICA INC (CLS) is 7 / 10.


Can you provide the expected EPS growth for CLS stock?

The Earnings per Share (EPS) of CELESTICA INC (CLS) is expected to grow by 49.74% in the next year.